SCHEMBL5618445

SCHEMBL5618445

CNc1nccn2c(-c3cc4ccccc4s3)cnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 5/20 0.52
▸ FGFR1 P11362 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.38
▸ MERTK Q12866 1/20 0.38
▸ IKBKB O14920 3/20 0.38
▸ PIK3CD O00329 2/20 0.38
▸ CHUK O15111 2/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ PIK3R1 P27986 1/20 0.38
▸ TNK2 Q07912 1/20 0.37
▸ EIF4E P06730 1/20 0.37
▸ MKNK1 Q9BUB5 1/20 0.37
▸ MKNK2 Q9HBH9 1/20 0.37
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ CYP19A1 P11511 1/20 0.36
▸ TTK P33981 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8239749 0.81 FYN (0.46) FLT3FGFR1ADORA3IKBKBTNK2
SCHEMBL5618442 0.79 FGFR1 (0.41) FLT3FGFR1MERTKIKBKBPIK3CD
SCHEMBL5401140 0.77 FLT3 (0.55) FLT3IKBKBCHUKTTKAURKA
SCHEMBL5619013 0.76 FLT3 (0.54) FLT3ADORA3TTKAURKAAURKB
SCHEMBL5403440 0.75 FLT3 (0.59) FLT3ADORA3TTKAURKB
SCHEMBL5618824 0.75 FLT3 (0.53) FLT3ADORA3IKBKBTTKAURKA
SCHEMBL5413872 0.74 FLT3 (0.55) FLT3ADORA3IKBKBCYP11B2TTK
SCHEMBL5618050 0.74 FLT3 (0.49) FLT3ADORA3CYP11B1CYP11B2TNK2
SCHEMBL5618679 0.73 FLT3 (0.64) FLT3ADORA3IKBKBTTK
SCHEMBL5404865 0.73 FLT3 (0.56) FLT3TTKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US claimed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 FLT3 216/4885FGFR1 662/4885ADORA3 2912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback